First-line nivolumab (NIVO) plus ipilimumab (IPI) versus chemotherapy (chemo) for the treatment of unresectable malignant pleural mesothelioma (MPM): Patient-reported outcomes (PROs) from CheckMate 743
Year: 2021
Type: conference-paper
Source: Pneumologie
Authors: H Bischoff, A Scherpereel, S Antonia, Y Bautista, F Grossi, D Kowalski, G Zalcman, A Nowak, N Fujimoto, S Peters, A Tsao, A Mansfield, S Popat, X Sun, B Padilla, P Aanur, M Daumont, B Bennett, M McKenna, P Baas
Institutions: University Hospital Heidelberg, Université de Lille, Moffitt Cancer Center, Centro Medico Nacional Siglo XXI, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, The Maria Sklodowska-Curie National Research Institute of Oncology, Université Paris Cité, Assistance Publique – Hôpitaux de Paris, Hôpital Bichat-Claude-Bernard, The University of Western Australia, Sir Charles Gairdner Hospital, Okayama Rosai Hospital, Centre Hospitalier Universitaire Vaudois, The University of Texas MD Anderson Cancer Center, Mayo Clinic, Institute of Cancer Research, Royal Marsden Hospital, Bristol-Myers Squibb (United States), Leiden University Medical Center, The Netherlands Cancer Institute
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4388197177